AU2014248198B2 - Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators - Google Patents

Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators Download PDF

Info

Publication number
AU2014248198B2
AU2014248198B2 AU2014248198A AU2014248198A AU2014248198B2 AU 2014248198 B2 AU2014248198 B2 AU 2014248198B2 AU 2014248198 A AU2014248198 A AU 2014248198A AU 2014248198 A AU2014248198 A AU 2014248198A AU 2014248198 B2 AU2014248198 B2 AU 2014248198B2
Authority
AU
Australia
Prior art keywords
human
angiogenesis
placental extract
placental
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014248198A
Other languages
English (en)
Other versions
AU2014248198A1 (en
Inventor
Peter S. Mcfetridge
Marc C. Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of AU2014248198A1 publication Critical patent/AU2014248198A1/en
Application granted granted Critical
Publication of AU2014248198B2 publication Critical patent/AU2014248198B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1347—Smooth muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • C12N2533/92—Amnion; Decellularised dermis or mucosa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
AU2014248198A 2013-04-02 2014-04-02 Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators Ceased AU2014248198B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361807401P 2013-04-02 2013-04-02
US61/807,401 2013-04-02
PCT/US2014/032696 WO2014165602A1 (en) 2013-04-02 2014-04-02 Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators

Publications (2)

Publication Number Publication Date
AU2014248198A1 AU2014248198A1 (en) 2015-10-29
AU2014248198B2 true AU2014248198B2 (en) 2018-11-29

Family

ID=51621067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014248198A Ceased AU2014248198B2 (en) 2013-04-02 2014-04-02 Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators

Country Status (8)

Country Link
US (2) US9821013B2 (enExample)
EP (1) EP2981273B1 (enExample)
JP (1) JP2016516091A (enExample)
KR (1) KR20150139569A (enExample)
AU (1) AU2014248198B2 (enExample)
CA (1) CA2908562A1 (enExample)
HK (1) HK1221402A1 (enExample)
WO (1) WO2014165602A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316602B (zh) 2005-09-27 2015-06-03 组织技术公司 羊膜制品和纯化的组合物及其使用方法
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
JP2016516091A (ja) 2013-04-02 2016-06-02 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 血管新生の誘導および調節のための組成物および方法、ならびに血管新生調節因子を同定する方法およびアッセイ
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
TWI720984B (zh) 2015-05-20 2021-03-11 美商帝聖工業公司 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2020036245A1 (ko) * 2018-08-17 2020-02-20 고려대학교 산학협력단 인간 신경줄기세포의 기능강화 및 생산을 위한 태반유래 세포 조건화 배지 및 이의 용도
US20210369630A1 (en) * 2018-10-17 2021-12-02 University Of Florida Research Foundation Magnetically responsive composite microparticles for triggered delivery of biologically active agents
EP3947637A1 (en) 2019-04-04 2022-02-09 THT Biomaterials GmbH A novel human-material-based platform technology for tissue engineering
WO2023038924A1 (en) * 2021-09-07 2023-03-16 Plakous Therapeutics, Inc. Acellular placental therapies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5976782A (en) * 1994-03-04 1999-11-02 The Australian University In-vitro angiogenesis assay
US20050002915A1 (en) * 2003-01-28 2005-01-06 Anthony Atala Enhancement of angiogenesis to grafts using cells engineered to produce growth factors
US20070128171A1 (en) * 2003-07-01 2007-06-07 Tranquillo Robert T Engineered blood vessels
US20120129775A1 (en) * 2009-07-31 2012-05-24 Enrique Zudaire Antiangiogenic small molecules and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
JP2770926B2 (ja) * 1985-12-17 1998-07-02 サイナーゲン インコーポレーテッド 毛管内皮細胞プロテアーゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
JPS63152322A (ja) * 1986-09-30 1988-06-24 Ichimaru Pharcos Co Ltd プラセンタ−組織由来フイブロネクチン含有溶液
CA2005600A1 (en) 1988-12-20 1990-06-20 Cal-Henrik Heldin Endothelial cell growth factor
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
JPH0931100A (ja) * 1995-07-24 1997-02-04 Nippon Ham Kk 変性コラーゲン及びその製造方法
CA2375617A1 (en) 1999-06-07 2000-12-14 Edwards Lifesciences Corporation Targeted angiogenesis
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
DE60234163D1 (de) * 2001-01-05 2009-12-10 Viromed Ltd Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti-angiogenes protein oder teile davon kodiert, enthalten
WO2003082305A1 (en) * 2002-04-03 2003-10-09 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
AU2003237078C1 (en) 2002-04-12 2009-10-08 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
JP2005065661A (ja) * 2003-08-20 2005-03-17 Akihiro Yamaguchi ヒト血管内皮細胞のＶＥＧＦ誘導性活性化及び血管新生におけるＩｄの役割
US7775965B2 (en) 2004-03-09 2010-08-17 The Board Of Regents Of The University Of Oklahoma Decellularized grafts from umbilical cord vessels and process for preparing and using same
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
CN101316602B (zh) * 2005-09-27 2015-06-03 组织技术公司 羊膜制品和纯化的组合物及其使用方法
US8003388B2 (en) * 2006-03-24 2011-08-23 Nortis, Inc. Method for creating perfusable microvessel systems
WO2008042441A1 (en) 2006-10-03 2008-04-10 Anthrogenesis Corporation Use of umbilical cord biomaterial for ocular surgery
CA2700613C (en) 2007-09-26 2022-09-20 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
WO2009100128A1 (en) * 2008-02-04 2009-08-13 Massachusetts Institute Of Technology Particulate delivery vehicles for embryoid bodies
SG188918A1 (enExample) * 2008-03-17 2013-04-30 Agency Science Tech & Res
US8685634B2 (en) * 2009-03-06 2014-04-01 University of Pittsburgh—of the Commonwealth System of Higher Education Neural scaffolds
KR101118017B1 (ko) 2009-09-04 2012-02-24 (주)차바이오앤디오스텍 태반 추출물을 제조하는 방법 및 태반 추출물
CN102822521B (zh) * 2010-03-30 2016-01-27 西门子公司 具有间接蒸发的太阳能热发电站和运行这种太阳能热发电站的方法
KR20140071813A (ko) 2012-12-04 2014-06-12 삼성전자주식회사 파이버 상에 형성된 저항성 메모리 소자 및 그 제종 방법
JP2016516091A (ja) 2013-04-02 2016-06-02 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 血管新生の誘導および調節のための組成物および方法、ならびに血管新生調節因子を同定する方法およびアッセイ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5976782A (en) * 1994-03-04 1999-11-02 The Australian University In-vitro angiogenesis assay
US20050002915A1 (en) * 2003-01-28 2005-01-06 Anthony Atala Enhancement of angiogenesis to grafts using cells engineered to produce growth factors
US20070128171A1 (en) * 2003-07-01 2007-06-07 Tranquillo Robert T Engineered blood vessels
US20120129775A1 (en) * 2009-07-31 2012-05-24 Enrique Zudaire Antiangiogenic small molecules and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MIYAGAMI ET AL., "Physiological changes in the pattem of placental gene expression eady in the first trimester", REPROD SCI., (2012-12-10), vol. 20, no. 6, pages 710 - 714 *
PRESTA ET AL., "Human placental tissue stimulates bovine capillary endothelial cell growth, migration and protease production", BIOSCI REP., (1985-09-01), vol. 5, no. 9, doi:10.1007/BF01119877, pages 783 - 790 *
THIEX ET AL., REPROD BIOL ENDOCRINOL., (2009-10-26), vol. 7, no. 117, doi:10.1186/1477-7827-7-117, pages 1 - 10 *

Also Published As

Publication number Publication date
KR20150139569A (ko) 2015-12-11
US20140294780A1 (en) 2014-10-02
US10300091B2 (en) 2019-05-28
CA2908562A1 (en) 2014-10-09
US20170209497A1 (en) 2017-07-27
EP2981273B1 (en) 2020-09-16
WO2014165602A1 (en) 2014-10-09
EP2981273A4 (en) 2016-10-26
EP2981273A1 (en) 2016-02-10
HK1221402A1 (zh) 2017-06-02
JP2016516091A (ja) 2016-06-02
AU2014248198A1 (en) 2015-10-29
US9821013B2 (en) 2017-11-21

Similar Documents

Publication Publication Date Title
US9821013B2 (en) Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators
Moore et al. Novel human-derived extracellular matrix induces in vitro and in vivo vascularization and inhibits fibrosis
Heltmann-Meyer et al. Gelatin methacryloyl is a slow degrading material allowing vascularization and long-term use in vivo
JP7854806B2 (ja) 幹細胞／前駆体の固形器官へのパッチ移植
Gu et al. Effects of dynamic mechanical stimulations on the regeneration of in vitro and in vivo cartilage tissue based on silk fibroin scaffold
Dohle et al. Macrophage-mediated angiogenic activation of outgrowth endothelial cells in co-culture with primary osteoblasts
CN105517587B (zh) 伤口愈合与组织工程
Rioja et al. Endothelial sprouting and network formation in collagen-and fibrin-based modular microbeads
Chi et al. Cardiac repair using chitosan-hyaluronan/silk fibroin patches in a rat heart model with myocardial infarction
Gholobova et al. Functional evaluation of prevascularization in one-stage versus two-stage tissue engineering approach of human bio-artificial muscle
KR101851925B1 (ko) 제대 조직―유래 세포를 사용한 말초 혈관 질환의 치료
KR20110106302A (ko) 암 치료를 위한 세포외 기질 조성물
Hao et al. A bioactive material with dual integrin-targeting ligands regulates specific endogenous cell adhesion and promotes vascularized bone regeneration in adult and fetal bone defects
US20120171768A1 (en) Collagen-based matrices for vessel density and size regulation
CN107427535A (zh) 经修饰的血凝块
Xie et al. Vascular endothelial growth factor attenuates neointimal hyperplasia of decellularized small-diameter vascular grafts by modulating the local inflammatory response
Zhang et al. Transplantation of olfactory ensheathing cells combined with chitosan down-regulates the expression of P2X7 receptor in the spinal cord and inhibits neuropathic pain
US20200360563A1 (en) Methods for Vascular Construction and Products Therefrom
Komez et al. A two-compartment bone tumor model to investigate interactions between healthy and tumor cells
CN120574767A (zh) 人胎盘源促血管干细胞hPASCs及其应用
EP2607478A1 (en) Phenanthroline treated MSC
Wu et al. Decellularized vascular matrix material–based TEVG coated with PRP for anti-degradation and anti-inflammation
Maiborodin et al. Angiogenesis in rat uterine scar after introduction after autological mesenchymal stem cells of bone marrow origin
AU2015255907A1 (en) Sustained release angiogenesis modulating compositions and methods for induction and modulation of angiogenesis
Alderfer Engineering Tunable Synthetic Biomaterials for Mechanistic and Therapeutic Lymphatic Vasculature Applications

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MCFETRIDGE, PETER S. AND MOORE, MARC C.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired